Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015000LC2
Thu, 19.12.2024
Mainz BioMed N.V.
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval
BERKELEY, US and MAINZ, Germany – December 19, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mai [ … ]
Fri, 29.11.2024
Mainz BioMed N.V.
Mainz Biomed Announces Stock Split
BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock sp [ … ]
Tue, 12.11.2024
Mainz BioMed N.V.
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
BERKELEY, US and MAINZ, Germany – November 12, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the [ … ]
Mon, 21.10.2024
Mainz BioMed N.V.
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Revenue increases 4% year over year while loss from operations decreases by 32%
Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8 [ … ]
Tue, 08.10.2024
Mainz BioMed N.V.
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden
BERKELEY, US and MAINZ, Germany – October 8, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnost [ … ]
Tue, 01.10.2024
Mainz BioMed N.V.
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
BERKELEY, US and MAINZ, Germany – October 1, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to sharehold [ … ]
Wed, 18.09.2024
Mainz BioMed N.V.
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection
BERKELEY, US and MAINZ, Germany – September 18, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company” [ … ]
Wed, 18.09.2024
Mainz BioMed N.V.
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection
BERKELEY, US and MAINZ, Germany – September 18, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company” [ … ]
Wed, 04.09.2024
Mainz BioMed N.V.
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis
BERKELEY, US and MAINZ, G [ … ]
Thu, 25.07.2024
Mainz BioMed N.V.
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
BERKELEY, US – MAINZ, Germany – July 25, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert prod [ … ]